Why does MK-677 affect sleep if it is a growth hormone compound?

GH secretion and slow-wave sleep are tightly coupled. MK-677 acts on GHSR-1a to amplify GH pulsatility; SWS enhancement is a consequence of this, confirmed in the Frieboes 1995 GHRP-6 study as a class-level mechanism.

Are CJC-1295 or Ipamorelin as well evidenced as MK-677 for sleep?

No. Both have the same GH/SWS mechanistic rationale but no dedicated PSG-based human sleep study. Their sleep benefit is mechanistically reasonable but evidence-extrapolated from MK-677 and GHRP-6 data, not directly confirmed.

Spoke 6.4 · Sleep & Circadian Peptides

MK-677 and sleep architecture: how a ghrelin receptor agonist amplifies slow-wave sleep through the GH-pulse axis.

Q: Does MK-677 actually improve sleep, or just make you drowsy?

Copinschi 1997 showed increased stage IV SWS and REM sleep with unchanged sleep onset latency — inconsistent with sedation. This profile matches GH-pulse amplification, not a sedative mechanism.

Q: Is there a Phase III sleep trial for MK-677?

No. Copinschi 1997 used PSG as a secondary endpoint in a GH/body-comp study. No pre-registered Phase III trial with sleep as a primary outcome has been conducted for MK-677 or any GH secretagogue.

Q: How does MK-677 sleep data compare to DSIP?

MK-677 is meaningfully better evidenced. Copinschi 1997 is a randomised, PSG-confirmed crossover; DSIP's human data are smaller, older, unreplicated, and come from a compound with no identified primary receptor. The evidence gap is substantial.

By PeptideRadar Research Desk · April 18, 2026

CompoundMK-677 (Ibutamoren) MechanismGhrelin receptor agonist → GH pulse → SWS amplification Key paperCopinschi et al., Neuroendocrinology 1997 FDA statusNot approved; no active NDA Updated2026-04-18

MK-677 has the strongest sleep-specific human evidence of any compound in the Sleep & Circadian cluster — not because it was designed as a sleep drug, but because the biological mechanism it engages (ghrelin receptor agonism → amplified nocturnal GH pulse) is tightly coupled to slow-wave sleep by a relationship that has been replicated across decades of sleep endocrinology research. This spoke covers the sleep-specific data only; the broader body-composition, IGF-1, and longevity evidence is covered in the Pillar 3 MK-677 overview.

Key points

MK-677 is a ghrelin receptor (GHSR-1a) agonist that stimulates pulsatile GH release from the pituitary. It is orally bioavailable, unlike most GH-axis peptides.
Nocturnal GH secretion is tightly coupled to slow-wave sleep (SWS, stages 3–4). The relationship is bidirectional: GH secretion promotes SWS; SWS is necessary for the peak GH pulse.
Copinschi et al. (1997, Neuroendocrinology): 8-week oral MK-677 treatment in healthy adults increased stage IV and REM sleep; no sedation effect on sleep onset latency.
Frieboes et al. (1995, Arch Gen Psychiatry): IV GHRP-6 (same receptor class) increased SWS duration; establishes class-level evidence for the mechanism.
MK-677's off-target effects — appetite stimulation, water retention, elevated fasting glucose — complicate its use as a standalone sleep intervention.
No dedicated Phase III sleep trial exists for MK-677 or any GH secretagogue.

The GH–slow-wave sleep coupling: the mechanistic foundation

Understanding why MK-677 affects sleep requires first understanding the normal relationship between growth hormone and sleep architecture. This relationship was systematically characterised by Van Cauter's group and reviewed in detail by Steiger (2002, Sleep Med Rev) and Vgontzas et al. (1999, J Clin Endocrinol Metab).

The key findings from this literature:

The nocturnal GH pulse is temporally linked to the first slow-wave sleep episode. In healthy young adults, peak GH secretion occurs within approximately 60–90 minutes of sleep onset, coinciding with the onset of stage 3–4 NREM sleep. This coupling is so reliable that GH pulsatility has been used as a proxy measure for SWS quality in clinical research.
The relationship is bidirectional. Blocking GH-releasing hormone (GHRH) with an antagonist reduces both GH secretion and SWS amplitude in human studies. Conversely, GHRH infusion increases both. This bidirectionality means GH-pulse-amplifying compounds have a principled, mechanism-anchored pathway to SWS enhancement.
The coupling declines with age. Both GH pulse amplitude and SWS depth decrease in parallel as people age — one of the reasons that GH-axis decline has been linked to changes in sleep quality in older adults. This is the theoretical therapeutic rationale for GH secretagogues in age-related sleep deterioration.
MK-677 specifically acts via the ghrelin receptor (GHSR-1a), not directly via GHRH. Ghrelin, the endogenous ligand for GHSR-1a, also promotes sleep in animal models. MK-677 mimics this ghrelin effect on GH release while being orally bioavailable — the property that made it attractive for prolonged-administration studies like Copinschi 1997.

Copinschi et al. 1997: the landmark study

The primary human evidence for MK-677's effect on sleep comes from Copinschi G and colleagues, published in Neuroendocrinology (1997;66(4):278–286). This is a study that merits careful reading rather than summary dismissal or uncritical endorsement.

Design: Randomised, double-blind, placebo-controlled crossover. Healthy male adults received oral MK-677 or placebo for 8 weeks. Polysomnography (PSG) was performed at baseline and at the end of each treatment period. PSG included standard sleep stage scoring (EEG, EOG, EMG), and GH secretion was measured by frequent blood sampling to characterise the nocturnal GH pulse.

Results on sleep architecture:

Stage IV (deep SWS) sleep increased significantly relative to placebo.
REM sleep duration increased.
Sleep onset latency was unchanged — confirming that the effect is not sedation-mediated.
Total sleep time was not significantly different.
Nocturnal GH pulse amplitude increased substantially, temporally correlated with the SWS enhancement.

Interpretation: The pattern — increased SWS and REM without changed onset latency or total sleep time — is the profile you would expect from GH-pulse amplification specifically, rather than from a general sedative or hypnotic. Benzodiazepines reduce REM sleep and SWS; Z-drugs reduce sleep onset but typically don't enhance SWS amplitude. MK-677's profile is qualitatively different and mechanistically distinct.

Limitations of Copinschi 1997: The study was small by current Phase II standards; the sample was restricted to healthy males, limiting generalizability to older adults, women, or people with existing sleep disorders. The 8-week duration demonstrates that the effect persists on chronic dosing, which is relevant, but it does not characterise what happens beyond 8 weeks with continuous treatment. The primary registration of this study was for body composition and GH-axis effects; sleep was a secondary endpoint. This is important: a pre-registered primary sleep endpoint trial for MK-677 does not exist.

Frieboes et al. 1995: class-level evidence

Frieboes RM and colleagues (1995, Arch Gen Psychiatry, 52(11):958–961) studied the effect of intravenous GHRP-6 — a hexapeptide growth hormone releasing peptide — on sleep architecture in normal adults. GHRP-6 acts on the same GHSR-1a receptor as MK-677 and ghrelin. The findings: IV GHRP-6 infusion increased slow-wave sleep, with the SWS enhancement temporally correlated with the induced GH pulse. This study is significant because it demonstrates the effect at the class level (ghrelin receptor agonism → SWS) using a different compound, increasing confidence that the effect is mechanism-driven rather than compound-specific.

The Frieboes study is smaller than Copinschi, used IV rather than oral administration, and had a single-night design — all limiting its standalone interpretive power. But in combination with Copinschi, it provides the two-study minimum for a class-level mechanistic claim: ghrelin receptor agonism amplifies slow-wave sleep through GH-pulse coupling.

What the GH–SWS coupling tells us about age and sleep

The age-related parallel decline of GH pulse amplitude and SWS depth is one of the more compelling reasons to investigate GH secretagogues for sleep in older populations specifically. Vgontzas et al. (1999) documented this decline and its correlation with subjective sleep quality deterioration. The Nass et al. (2008, Ann Intern Med) Phase III-scale MK-677 study in healthy older adults (which primarily targeted body composition and functional outcomes) incidentally showed effects on subjective sleep quality, consistent with the Copinschi findings in a different age group. Sleep was not a primary endpoint in the Nass study, and the PSG data were not the focus — but the signal directional consistency is notable.

Van Cauter et al. (2000, J Clin Invest) used gamma-hydroxybutyrate (GHB) — a different compound acting through different receptors — to simultaneously increase GH secretion and SWS, independently validating the coupling from a non-peptide direction. This convergent evidence from multiple mechanisms and compounds is what gives the GH/SWS coupling its mechanistic credibility, and why GHRH-axis peptides in general have a stronger sleep rationale than DSIP (which lacks confirmed receptor pharmacology entirely).

The side-effect profile: why this matters for sleep research

MK-677's ghrelin receptor agonism produces appetite stimulation as a consistent, dose-dependent side effect — ghrelin is the primary hunger-signalling hormone, and MK-677's agonism is not selective between GH-releasing and appetite-stimulating ghrelin receptor signalling. For a compound used at daytime dosing for body composition, appetite stimulation is a secondary concern. For a compound being investigated specifically for sleep, nocturnal dosing (which some research protocols use to time GH pulse amplification) may limit appetite effects but does not eliminate them.

Additional side effects documented in the chronic-use literature include water retention (edema), elevated fasting glucose, and potential insulin resistance with long-term use. Svensson et al. (1998) documented these in a two-month study of obese subjects. These profiles are not trivial and are the reason MK-677 should not be framed simply as a "sleep supplement." Our MK-677 side effects spoke in the Longevity pillar covers the full safety profile; this page focuses on the sleep-specific angle.

How this fits in the Sleep & Circadian cluster

MK-677 is the best-evidenced compound for sleep in the Sleep & Circadian pillar, with two published human studies using polysomnography as an objective outcome. It sits at the top of the evidence hierarchy in this cluster by a significant margin over DSIP (pre-Phase II, no receptor) and Epitalon (Russian data, no independent replication).

Within the GH-axis sleep sub-cluster, the mechanistic rationale extends to other GHSR agonists and GHRH analogs, though none have the same direct PSG evidence:

Growth hormone and slow-wave sleep (6.14): the underlying endocrinology, mechanism depth
CJC-1295 and sleep quality (6.15): GHRH analog — rationale extrapolated from GH/SWS coupling, no direct PSG trial
Ipamorelin sleep spoke (6.20): selective GHRP — same mechanism class as GHRP-6 (Frieboes), no dedicated sleep trial
Sermorelin and sleep (6.16): GHRH analog with different half-life profile
Peptides for deep sleep (6.9): practical overview for researchers focused on SWS specifically

For researchers comparing MK-677 to DSIP on sleep evidence, the DSIP deep-dive spoke makes the contrast explicit. For the comparison between MK-677 and Ipamorelin more broadly, see the MK-677 vs Ipamorelin spoke in Pillar 3. The broader pharmacology of MK-677 — body composition, IGF-1 axis, longevity rationale — is covered in the MK-677 overview spoke in Pillar 3; this page intentionally does not duplicate that content.

Where to read further

Primary references, current to 2026-04:

Copinschi G, et al. "Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man." Neuroendocrinology. 1997;66(4):278–286.
Frieboes RM, et al. "Growth hormone-releasing peptide-6 promotes slow-wave sleep in normal adults." Arch Gen Psychiatry. 1995;52(11):958–961.
Steiger A. "Sleep and the hypothalamo-pituitary-adrenocortical system." Sleep Med Rev. 2002;6(2):125–138.
Van Cauter E, et al. "Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men." J Clin Invest. 2000;100(3):745–753.
Nass R, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults." Ann Intern Med. 2008;149(9):601–611.
Svensson J, et al. "Two-month treatment of obese subjects with the oral growth hormone secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." J Clin Endocrinol Metab. 1998;83(2):362–369.
Vgontzas AN, et al. "Sleep, sleepiness, and growth hormone." J Clin Endocrinol Metab. 1999;84(6):1889–1894.

Frequently asked

Does MK-677 actually improve sleep, or just make you drowsy?

The Copinschi 1997 data show increased stage IV slow-wave sleep and REM sleep with unchanged sleep onset latency — this is a profile inconsistent with sedation. Sedatives and hypnotics generally reduce sleep onset latency; benzodiazepines suppress REM sleep. MK-677's profile shows improved sleep architecture quality (deeper SWS, more REM) without the sedative signature, consistent with GH-pulse amplification specifically. This is a qualitatively different effect from a sleeping pill.

Why does MK-677 affect sleep if it's a growth hormone compound?

Because GH secretion and slow-wave sleep are tightly coupled. The largest nocturnal GH pulse occurs during the first SWS episode of the night; the relationship is bidirectional (GH-releasing hormone simultaneously promotes GH release and SWS). MK-677 acts on the ghrelin receptor (GHSR-1a) to amplify GH pulsatility — the SWS enhancement is a consequence of this GH-pulse amplification, not a separate direct sleep mechanism. The Frieboes 1995 study with GHRP-6 (same receptor class) confirms the class-level mechanism.

Is there a Phase III sleep trial for MK-677?

No. The Copinschi 1997 study used PSG as an endpoint, but sleep was not the primary registered endpoint; it was a secondary measurement in a study primarily tracking GH secretion and body composition. The Nass 2008 study (sometimes described as Phase III-scale) targeted body composition in older adults and showed subjective sleep improvements, but also did not use PSG as a primary endpoint. No pre-registered Phase III trial with sleep as the primary outcome has been conducted for MK-677 or any GH secretagogue.

How does MK-677 sleep data compare to DSIP?

MK-677 is meaningfully better evidenced for sleep. Copinschi 1997 is a randomised, placebo-controlled crossover study with PSG as an objective endpoint. DSIP's human data (Schneider-Helmert 1983) used smaller samples, older methods, and has not been replicated in adequately powered modern trials. More critically, DSIP has no identified primary receptor, making mechanistic interpretation impossible; MK-677 has a confirmed GHSR-1a mechanism with quantified receptor pharmacology. The evidence gap between them is substantial.

Can MK-677 be used specifically as a sleep aid?

This is outside the RUO framing of PeptideRadar content. What the research shows is that MK-677 increases slow-wave and REM sleep in normal adults. However, MK-677 also increases appetite substantially, causes water retention, and may impair insulin sensitivity with chronic use — these side effects exist whether the compound is used for body composition or for sleep. A compound that improves sleep quality while increasing appetite and fluid retention is not straightforwardly a "sleep aid." The side-effect profile must be weighed alongside any sleep benefit.

What about CJC-1295 or Ipamorelin for sleep — are they as well evidenced as MK-677?

No. CJC-1295 and Ipamorelin act on different parts of the GH axis (GHRH receptor and ghrelin receptor, respectively) and have the same theoretical rationale for SWS enhancement through GH-pulse amplification. But neither has a dedicated PSG-based human sleep study equivalent to Copinschi 1997. The inference that they improve sleep is mechanistically reasonable but evidence-extrapolated, not data-confirmed. Our CJC-1295 sleep spoke and Ipamorelin sleep spoke address this explicitly.

Reviewer sign-off Reviewed 2026-04-18 by the PeptideRadar Research Desk. This spoke covers MK-677's sleep-specific evidence only. The broader MK-677 pharmacology — body composition, IGF-1, longevity framing — is covered in the Pillar 3 MK-677 overview (mk-677-ibutamoren.html). MK-677 is an investigational compound; no FDA-approved indication exists as of 2026. All content is research-use-only. Corrections policy: errors flagged in a dated note, not silently edited. Contact: corrections@peptideradar.net.